What we know about effective public engagement on CRISPR and beyond.

deliberation political communication public engagement public participation science communication

Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
01 06 2021
Historique:
entrez: 29 5 2021
pubmed: 30 5 2021
medline: 1 12 2021
Statut: ppublish

Résumé

Advances in gene editing technologies for human, plant, and animal applications have led to calls from bench and social scientists, as well as a wide variety of societal stakeholders, for broad public engagement in the decision-making about these new technologies. Unfortunately, there is limited understanding among the groups calling for public engagement on CRISPR and other emerging technologies about 1) the goals of this engagement, 2) the modes of engagement and what we know from systematic social scientific evaluations about their effectiveness, and 3) how to connect the products of these engagement exercises to societal decision or policy making. Addressing all three areas, we systematize common goals, principles, and modalities of public engagement. We evaluate empirically the likely successes of various modalities. Finally, we outline three pathways forward that deserve close attention from the scientific community as we navigate the world of Life 2.0.

Identifiants

pubmed: 34050014
pii: 2004835117
doi: 10.1073/pnas.2004835117
pmc: PMC8179128
pii:
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

The authors declare no competing interest.

Références

Science. 2003 Feb 14;299(5609):977
pubmed: 12586907
Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1274-1276
pubmed: 31911470
Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7692-7697
pubmed: 30642954
Science. 2017 Aug 11;357(6351):553-554
pubmed: 28798120
PLoS One. 2016 Feb 25;11(2):e0148867
pubmed: 26913869
Risk Anal. 2011 Feb;31(2):324-34
pubmed: 21039705
Proc Natl Acad Sci U S A. 2014 Sep 16;111 Suppl 4:13593-7
pubmed: 25225372
Proc Natl Acad Sci U S A. 2014 Sep 16;111 Suppl 4:13585-92
pubmed: 25225389
Dev Sci. 2013 Jul;16(4):622-38
pubmed: 23786479
Public Underst Sci. 2018 Aug;27(6):655-673
pubmed: 28490253
Nature. 2015 Jun 25;522(7557):413-4
pubmed: 26108836
Nature. 2018 Mar 22;555(7697):435-437
pubmed: 29565415
Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7662-7669
pubmed: 30642953

Auteurs

Dietram A Scheufele (DA)

Department of Life Sciences Communication, University of Wisconsin-Madison, Madison, WI 53706; scheufele@gmail.com.
Morgridge Institute for Research, Madison, WI 53715.

Nicole M Krause (NM)

Department of Life Sciences Communication, University of Wisconsin-Madison, Madison, WI 53706.

Isabelle Freiling (I)

Department of Communication, University of Vienna, 1090 Vienna, Austria.

Dominique Brossard (D)

Department of Life Sciences Communication, University of Wisconsin-Madison, Madison, WI 53706.
Morgridge Institute for Research, Madison, WI 53715.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH